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Severe fever with thrombocytopenia syndrome (SFTS) virus
(SFTSV) is an emerging tick-borne virus classified within the
Banyangvirus genus. SFTS disease has been reported throughout
East Asia since 2009 and is characterized by high fever, thrombo-
cytopenia, and leukopenia and has a 12 to 30% case fatality rate.
Due to the recent emergence of SFTSV, there has been little time
to conduct research into preventative measures aimed at combat-
ting the virus. SFTSV is listed as one of the World Health Organi-
zation’s Prioritized Pathogens for research into antiviral therapeutics
and vaccine development. Here, we report 2 attenuated recombinant
SFTS viruses that induce a humoral immune response in immunized
ferrets and confer complete cross-genotype protection to lethal chal-
lenge. Animals infected with rHB29NSsP102A or rHB2912aaNSs (both
genotype D) had a reduced viral load in both serum and tissues and
presented without high fever, thrombocytopenia, or mortality
associated with infection. rHB29NSsP102A- or rHB2912aaNSs-
immunized animals developed a robust anti-SFTSV immune re-
sponse against cross-genotype isolates of SFTSV. This immune re-
sponse was capable of neutralizing live virus in a focus-reduction
neutralization test (FRNT) and was 100% protective against a
cross-genotype lethal challenge with the CB1/2014 strain of SFTSV
(genotype B). Thus, using our midsized, aged ferret infection
model, we demonstrate 2 live attenuated vaccine candidates against
the emerging pathogen SFTSV.
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Severe fever with thrombocytopenia syndrome (SFTS) virus(SFTSV) is an emerging viral pathogen classified within the
Huaiyangshan banyangvirus species, Banyangvirus genus of the
Phenuiviridae family (1). First reported in China in 2009 (2),
cases of SFTS disease and subsequent virus isolations have been
described in Japan (3), South Korea (4–6), and more recently in
Vietnam (7). The virus is considered by the World Health Or-
ganization to be a pathogen “likely to cause wide epidemics” and
requires urgent scientific attention to be directed toward the
development of antiviral therapies and novel vaccines (8, 9).
SFTSV is maintained in nature by an enzootic tick–suspected
animal–tick cycle (10). Haemaphysalis longicornis is implicated as
one of the main vectors of SFTSV (11) and their increased ac-
tivity from March through November correlates with the epi-
demic season of SFTSV (10, 12). SFTSV infection in humans is
believed to be predominantly mediated through the bite of a
virus-infected tick. However, in 2012, human-to-human trans-
mission of SFTSV was described through contact with, or ex-
posure to, blood of SFTS index patients (13). Subsequent
reported human-to-human transmissions of SFTSV are thought
to have occurred among families, residents of villages where
patients lived, and even in hospital settings (14–16). When
secondary SFTS cases occurred, they were often fatal and dis-
played similar symptoms of infection to those seen in the index
patients, presenting with high viral loads in serum and low
platelet counts being reported (17).
SFTSV causes an often-fatal disease (12 to 15% case fatality
rate) that is characterized by thrombocytopenia, hemorrhagic
manifestations, and multiorgan failure (2, 18). To date, there
have been ∼8,500 reported cases of SFTS disease in China, more
than 100 laboratory confirmed cases in both South Korea (4–6)
and Japan (3, 19), and 2 cases reported in Vietnam (7).
Members of the Phenuiviridae family contain a trisegmented
single-stranded RNA genome of negative or ambisense polarity,
encoding 5 or 6 proteins (20, 21). The 3 genomic RNA segments
are designated the large (L), medium (M), and small (S) seg-
ments. The L segment encodes the viral RNA-dependent RNA
polymerase, the M segment encodes the 2 viral envelope glyco-
proteins (Gn and Gc), and the S segment encodes the nucleo-
capsid protein (N) and a nonstructural protein (NSs) in an
ambisense manner (22).
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Phylogenetic analysis of SFTSV strains isolated to date suggest
that 6 genotypes (A to F) circulate in East Asia, and that
genotype reassortment is commonly detected. The genotyping
roughly correlates phylogeographically, although the nomencla-
ture in the current literature is not consistently applied. Geno-
types A, B, D, and F have been isolated in South Korea,
genotypes B and E in Japan, and all genotypes have been iso-
lated in China (12, 23, 24).
The nonstructural protein (NSs) of phenuiviruses, in particular
that of SFTSV, is a well-characterized innate immune antagonist
and virulence factor (25–31). NSs acts as an antagonist to IFN
signaling to evade the expression of antiviral genes (28, 31, 32).
Previously, we have described 2 viruses that are unable to in-
teract with mammalian innate immune pathways such as the
IFN-β induction and signaling cascades and the TPL2 signaling
pathway. These viruses, rHB2912aaNSs (33) and SFTSV-PA
(herein known as rHB29NSsP102A) (31), contain a carboxyl-
terminal truncated short 12 amino acid peptide sequence derived
from the NSs open-reading frame (ORF) or have a single point
mutation in the NSs coding sequence from proline to alanine at
position 102, respectively. Both viruses demonstrated an inability
to antagonize mammalian innate immune responses to viral in-
fection in vitro. Additionally, rHB29NSsP102A was shown to be
attenuated in vivo in C57BL/6 wild-type mice that had been
pretreated with an anti-IFN-α/β receptor 1 (IFNAR1)-blocking
antibody prior to infection (31).
Many rodent models for SFTSV have been developed in re-
cent years, but no one model completely recapitulated the SFTS
disease phenotype seen in human cases (34). Infection with
SFTSV is only lethal to newborn rodents or genetically modified
immunocompromised animals (35–38); even experimentally in-
fected Rhesus macaques (39) and Cynomolgus macaques (34) do
not develop a lethal disease. Recently, we described an immu-
nocompetent age-dependent ferret model for SFTSV that re-
capitulated all SFTS disease pathologies, as evidenced by high
viral loads in serum and tissues, thrombocytopenia, leukopenia,
and a 93% mortality rate (40).
Since the discovery of the virus, there has been minimal work
published on the development of antiviral therapies or vaccine
candidates, and there is currently no commercially available
vaccine to prevent SFTSV. Thus, it is of high priority to develop
and evaluate potential vaccines to control and halt the spread of
this rapidly emerging infectious agent. Work has focused on a
recombinant NSs protein vaccine (41), a DNA vaccine based on
plasmids expressing the N or NSs proteins (42) or a recombinant
vesicular stomatitis virus (rVSV)-based vaccine candidate
expressing the SFTSV Gn/Gc glycoproteins (43). One thera-
peutic agent has also been developed through the characteriza-
tion of an antibody isolated from an infected patient. Here, the
authors demonstrated that this antibody conferred protection to
a lethal SFTSV challenge (44).
In this paper, we bring together previously developed
recombinant viruses and the newly described ferret model of
infection to assess the efficacy of these viruses as live attenuated
vaccine candidates. We show that while infection with a genotype
D Korean strain of SFTSV (CB8/2016) was lethal in our ferret
model, infection of the animals with recombinant viruses, in-
cluding a wild-type derived recombinant Chinese isolate (rHB29;
genotype D) resulted in a mild self-resolving infection devoid of
fever. Infected animals experienced no thrombocytopenia, had
reduced viral RNA levels in both serum and tissues and all an-
imals survived infection. These animals developed a robust anti-
SFTSV humoral immune response against homologous and
heterologous genotypes of SFTSV by 14 d post inoculation and
this immune response was 100% protective against a cross-
genotype lethal challenge with the CB1/2014 strain (genotype B).
Further, rHB2912aaNSs showed no reversion to wild type during
serial passage in vitro and in vivo. It is of note, that both CB8/
2016 and HB29 are genotype D wild-type viruses isolated
from infected patients. However, as demonstrated, HB29 is less
virulent in our ferret model of infection. The further deletion
or mutation of the NSs ORF as seen in rHB2912aaNSs or
rHB29NSsP102A respectively, further attenuates these viruses
(2, 45).
Thus, we demonstrate genetically stable, safe, live attenuated
vaccine candidates against the emerging pathogen SFTSV.
Results
Recombinant SFTS Viruses Do Not Induce Lethal Disease in a Ferret
Model.We recently described an age-dependent ferret model for
SFTS disease where infected animals demonstrated reduced
white blood cell counts, severe thrombocytopenia, high fever and
a high mortality rate (40). We used this model to assess the
virulence of recently described recombinant SFTS viruses
(rHB2912aaNSs and rHB29NSsP102A) and assessed their suit-
ability as live-attenuated vaccine candidates (31, 33).
Groups of 12 ferrets were inoculated intramuscularly (i.m.)
with 2 wild-type viruses: The first, a Korean strain of SFTSV
(CB8/2016; SI Appendix, Table S1); the second, recombinant
mutant SFTS viruses from genotype D that were isolated in
China (all based on sequences from a Chinese patient isolate,
HB29; SI Appendix, Table S1). Body temperature and weight-
change measurements were recorded and blood collection for
hematology analysis were performed on 0-, 2-, 4-, 6-, 8-, 10-, and
12-d postinfection (p.i.). The results showed that although
rHB29-infected animals showed slightly increased fever and
weight loss over time, significant weight loss and fever were not
observed in animals infected with rHB29 or either of the NSs-
mutant viruses. Animals infected with the CB8/2016 strain
recorded an average weight loss of 12% by 8 d p.i. (Fig. 1A), and
a marked fever was observed from 4 d p.i. (2.3 °C increase). The
recorded fever remained high until the cessation of the experi-
ment (Fig. 1 A and B).
To demonstrate the association between clinical symptoms
and virus replication in infected animals, we tested for the
presence of viral RNA in the serum by qRT-PCR. All 4 viruses
were detected in the sera of infected animals with rHB29 repli-
cating to statistically higher levels than rHB2912aaNSs at days 4
and 6 p.i., whereas viral RNA from CB8/2016 was detected in the
sera of infected animals from day 2 p.i. Peak RNA amounts of
1.62, 0.82, and 0.62 log10 viral copies per 1 mL were observed at 4
d p.i. in rHB29-, rHB29NSsP102A-, and rHB2912aaNSs-infected
animals, respectively, before being cleared to undetectable levels
by day 8 p.i. However, in animals infected with strain CB8/2016,
viral RNA levels rose consistently over the course of the exper-
iment peaking at 4.9 log10 viral copies per 1 mL at 10 d p.i. Viral
copy numbers of CB8/2016 recorded in the serum were consis-
tently and statistically greater than those recorded in animals
infected with the other SFTS viruses (Fig. 1C). Three of the
animals infected with CB8/2016 died at day 8 p.i., and all other
ferrets infected with CB8/2016 succumbed to infection by 12
d p.i. No mortality was associated with infection of animals
with either rHB29, rHB29NSsP102A, or rHB2912aaNSs viruses
(Fig. 1D).
Tissue Distribution of Recombinant SFTS Viruses. To further dem-
onstrate the dissemination of rHB29, rHB29NSsP102A, and
rHB2912aaNSs in infected ferrets, 3 ferrets of each group were
killed at days 4 and 6 p.i., and viral RNA copy numbers in lung,
liver, kidney, spleen, and intestines were assessed by qRT-PCR
(Fig. 2). In rHB29-infected animals, viral RNA was detectable at
low levels in all tissues with the exception of intestine. Peak virus
copy number (2.1 log10 viral copies/g) was recorded in the
spleen at day 6 p.i. (Fig. 2A). This pattern of tissue tropism and
replication was also observed in the tissue samples assayed from
rHB29NSsP102A-infected animals (Fig. 2B). This result was expected
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as these viruses only differ by one amino acid within the NSs
ORF (31). When tissues from ferrets infected with rHB2912aaNSs
were analyzed, a difference in virus tissue distribution was noted.
rHB2912aaNSs was only detected in the liver and spleen of in-
fected animals (1.29 log10 viral copies/g), peaking at 4 d p.i. Viral
genome copy numbers detected in the lung, kidney, and intestines
of these animals were recorded at or just above the limit of de-
tection (Fig. 2C).
In CB8/2016-infected animals, viral RNA levels were high in
all tissues assayed, with peak viral RNA levels detected in the
spleen (4.2 log10 viral copies/g) at 6 d p.i. A statistically signifi-
cant increase in CB8/2016 virus copy number from 68 to 525
genome copies was also noted in the liver between 4 and 6 d p.i.,
respectively. CB8 replication was also detected in the intestines
of infected ferrets (0.87 log10 viral copies/g) at day 6 p.i., dem-
onstrating a higher virulence and systemic spread of this virus
compared to the other 3 viruses tested (Fig. 2D).
Hematological Analysis of Blood from Infected Ferrets. One of the
hematological pathologies’ characteristic of SFTS disease is a
marked thrombocytopenia in infected patients and animals (2,
40). We examined platelet levels in the blood of animals infected
with the 4 different viruses (Fig. 3). The expected normal range
of platelets in laboratory ferrets is 171.1 to 1,280.6 × 103/μL (46).
From 4 d p.i., several animals infected with rHB29 recorded
platelet counts lower than the paired control sample taken
on day 0 p.i. However, there was no statistical reduction in mean
platelet counts observed at any time point analyzed (Fig. 3A).
None of the animals infected with either of the NSs-mutant
viruses developed thrombocytopenia over the course of in-
fection, and recorded mean platelet counts in these groups
remained steady or even increased with time (Fig. 3 B and C).
CB8/2016-infected animals developed a statistically significant
thrombocytopenia by 6 d p.i., and this continued until 8 d p.i.,
where several animals had platelet counts below the expected
normal range (Fig. 3D). The average platelet count at 8 d p.i.
for animals infected with CB8/2016 was only 153 × 103/μL,
compared to that of 533, 851, or 758 × 103/μL in blood from
rHB29-, rHB29NSsP102A-, or rHB2912aaNSs-infected animals,
respectively.
Hematological cell counts and blood chemistries were also
analyzed on blood sampled from the infected animals (SI Ap-
pendix, Fig. S1). A decrease in white blood cell count was only
observed in CB8/2016-infected ferrets at 6 d p.i. (SI Appendix,
Fig. S1A). No decrease in red blood cell counts were observed
(SI Appendix, Fig. S1B). Alanine aminotransferase (ALT) or
aspartate (AST) levels were also measured in the infected blood
samples. Increased ALT and AST levels were detected in
rHB29- and CB8/2016-infected samples over time, whereas no
Fig. 1. Relative body weight, temperature change, serum viral RNA copy number, and survival of aged ferrets infected with recombinant SFTS viruses. (A–D)
Twelve ferrets in each group were inoculated with 4 × 106 PFUs of rHB29 (red), 4 × 106 PFUs of rHB29NSsP102A (blue), 5 × 10
5 PFUs of rHB2912aaNSs (green), or
5 × 105 PFUs of CB8/2016 (purple). Relative weight (A), temperature (B), viral RNA copy number in the serum (C), and survival (D) were assessed at the in-
dicated times p.i., and mean values are shown ± SEM. The asterisks indicate significance compared to each day p.i. sample analyzed by one-way ANOVA with
Dunnett multiple comparison test (A–C) or the 2-tailed Mantel–Cox method (D). *P = 0.0424, **P = 0.0023 and ***P < 0.0134 (A); *P = 0.0007, **P < 0.0001,
***P = 0.0113 and ****P = 0.0032 (B); *P = 0.0031, **P = 0.0192, ***P = 0.0214, ****P = 0.0378, *****P = 0.0001, and ******P < 0.0001, (C); and *P < 0.0001
(D). # Sample not tested as animals had died/been killed.
Fig. 2. Distribution and viral RNA copy number in tissues of SFTSV-infected
ferrets. Tissues (n = 3 per group) from ferrets infected with rHB29 (A),
rHB29NSsP102A (B), rHB2912aaNSs (C), or CB8/2016 (D) were collected at days
4 (solid shapes) and 6 p.i. (open shapes), and viral RNA copy numbers were
assessed with real-time PCR. Examined tissues included lung, liver, kidney,
spleen, and intestine. The asterisks indicate significance compared to
each day p.i. sample by the 2-tailed, unpaired t test (*P = 0.0195). Each ex-
periment was performed for 3 biological and 3 technical repeats.
26902 | www.pnas.org/cgi/doi/10.1073/pnas.1914704116 Yu et al.
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changes were detected in either enzyme level following
rHB2912aaNSs infection (SI Appendix, Fig. S1 C and D).
Infection with Recombinant SFTS Viruses Induce Robust Antibody
Responses in SFTSV-Infected Animals. To investigate the immuno-
genicity of the recombinant viruses, we examined the anti-
SFTSV humoral immune responses in infected ferrets. A nu-
cleocapsid protein (N)-based enzyme-linked immunosorbent
assay (ELISA) was performed with serially diluted ferret sera
collected at 0, 8, 14, and 58 d p.i. (Fig. 4 A–C). Sera from rHB29-
infected ferrets showed an increase in optical density (OD)
values measured at day 8 and day 14 p.i.. It is noteworthy that
although the OD values recorded in sera from rHB29NSsP102A-
and rHB2912aaNSs-infected ferrets at 8 d p.i. were lower than
that of parental rHB29-infected group, both groups showed
significantly increased OD values (compared to day 0 p.i.) by 14
d p.i. The antibody responses seen may be correlated with
the relatively low virus RNA detected in sera and tissues of
rHB29NSsP102A- or rHB2912aaNSs-infected ferrets. At 14 d p.i.,
OD values of 1.0 were achieved with dilutions of 7.63, 7.10, or
4.11 (10log2) of rHB29-infected (Fig. 4A), rHB29P102A-infected
(Fig. 4B), or rHB2912aaNSs-infected (Fig. 4C) animal sera, re-
spectively. These data demonstrate that a reduced humoral im-
mune response was initiated in the NSs-deletant virus-infected
animals. OD signals were still detectable when fresh serially di-
luted serum samples were assayed at 58 d (approximately 8 wk)
p.i. prior to the administration of a lethal virus challenge
with CB1/2014.
To further characterize the immunogenicity of each
recombinant virus, we evaluated in vitro neutralization capabil-
ities of the ferret sera by using a 50% focus reduction neutrali-
zation test (FRNT50) with the serum samples collected at the
indicated time points post initial virus challenge (Fig. 4 D–F).
Similar to the ELISA data presented in Fig. 4 A–C, the parental
rHB29-infected ferrets showed the highest neutralization titers
against both genotype D (HB29 and CB8/2016) and B (CB1/
2014) viruses. Neutralization titres recorded from the rHB29-
infected animal sera were detectable by day 8 p.i. and peaked
at day 14 p.i. The peak FRNT50 values obtained at day 14 p.i.
were 5.5, 5.8, and 4.3 FRNT50 (10log2) for the neutralization of
rHB29, CB8/2016, or CB1/2014 viruses, respectively (Fig. 4 D–
F). Although the FRNT50 value of sera from rHB29NSsP102A-
and rHB2912aaNSs-infected ferrets at 8 d p.i. was lower than the
sera from that of the parental rHB29-infected group, they
showed significantly increased FRNT50 values by 14 d p.i. from
2.5 to 3.3 FRNT50 (10log2) against genotype D strains (rHB29
and CB8/2016). Further, both sera from rHB29NSsP102A- and
rHB2912aaNSs-infected animals showed neutralization titers of
2.5 FRNT50 (10log2) against heterologous genotype B SFTSV
strain, CB1/2014 on day 14 p.i. (Fig. 4F). The FRNT50 values of
each ferret sera remained stable until 58 d p.i. (Fig. 4 D–F).
These results suggest that preimmunization with rHB29NSsP102A
or rHB2912aaNSs could induce robust production of cross-
neutralizing antibodies against homologous and heterologous
SFTSV strains.
Immunization of Animals with Recombinant SFTS Viruses Confers
Cross-Clade Protection in a Lethal Challenge Model. We next wanted
to examine whether a single prior infection of the ferrets with
either rHB29, rHB29NSsP102A, or rHB2912aaNSs conferred
protective immunity. At 8 wk p.i., the surviving animals were
challenged with the genotype B, CB1/2014 strain of SFTSV. Six
animals in each group were challenged i.m. with 5 × 107 plaque-
forming units (PFUs) and their survival, weight change, tem-
perature, and viral RNA loads were measured for 12 d. At 5
d postchallenge (p.c.), 3 animals were killed per group to analyze
tissue tropism and assess viral dissemination by qRT-PCR (Fig.
5). Remarkably, all of the animals previously infected with ei-
ther rHB29, rHB29NSsP102A, or rHB2912aaNSs survived the
lethal challenge with CB1/2014, whereas all challenge virus only
controls died by 10 d p.i. (Fig. 5A). No weight loss was recorded
over the course of the infection in preimmunized animals (Fig.
5B), and only a mild transient fever was detected the rHB2912aaNSs-
immunized ferrets (Fig. 5C). Further, no thrombocytopenia was
detected in the immunized and challenged animals at any point
during the infection time course (Fig. 5 D–G). Platelet counts
in the rHB29- or rHB29NSsP102A-immunized ferrets rose from
a mean count of 518 × 103/μL on day 0 to 792 × 103/μL on day 8
following CB1/2014 challenge (Fig. 5 D and E), whereas
platelet counts remained stable in the rHB2912aaNSs-
immunized, CB1/2014-challenged ferrets throughout the
course of infection (Fig. 5F). Platelet counts in the CB1/2014-
infected challenge only group were reduced from day 4 p.c. and
continued to decrease until the cessation of the experiment
(Fig. 5G).
No Virus Replication Evident in Immunized Animals following
Challenge. Following the lethal challenge of immunized ferrets
with CB1/2014, serum samples were analyzed for the presence of
viral RNA (Fig. 6A). In rHB29NSsP102A-immunized ferrets,
CB1/2014 viral RNA was detected in the serum at 0.27 log10 viral
copies/mL at 2 d p.c., reaching peak copy numbers of 0.3 log10
viral copies/mL at day 6 p.c. A similar pattern of serum viral
RNA copy numbers was recorded in CB1/2014-challenged
rHB2912aaNSs-immunized animals, whereas no viral RNA was
detected in the serum of the rHB29-immunized group. CB1/2014
viral RNA was found in the serum of the challenge only group
and was detectable from day 2 p.c. (0.9 log10 viral copies/mL)
and continued to rise until day 8 p.c. (4.8 log10 viral copies/mL;
Fig. 6A). No changes in blood cell parameters were noted in
Fig. 3. Hematological analysis of platelets in SFTSV-inoculated ferrets.
Blood from infected ferrets was collected every other day, and hematolog-
ical examination was performed using a Celltac hematology analyzer.
Platelet counts from rHB29 (A), rHB29NSsP102A (B), rHB2912aaNSs (C), or
CB8/2016 (D) are shown. Normal ranges of platelet counts in ferrets are
171.7 to 1,280.6 × 103/μL and 2.5 to 16.7 × 106/μL, respectively (46, 58). The
dashed lines indicate the normal values of platelet counts. The asterisks in-
dicate significance compared to each day p.i. sample by one-way ANOVA
with Dunnett multiple comparison test. *P = 0.0404 (A) and *P = 0.0016 and
**P = 0.0002 (D). Each experiment was performed for 3 biological and 3
technical repeats.
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either rHB29NSsP102A- or rHB2912aaNSs-immunized animals
following virus challenge (SI Appendix, Fig. S2 A and B). Tran-
sient increases in serum ALT or AST levels were noted in
rHB29- or rHB2912aaNSs-immunized animals after virus
challenge (SI Appendix, Fig. S2 C and D), while both ALT and
AST levels rose steadily over the course of infection in the blood
samples taken from the CB1/2014 challenge only animals (SI
Appendix, Fig. S2 C and D).
Fig. 4. Specific humoral immune responses detected in infected ferrets. Serum from ferrets surviving an initial infection with rHB29 (A), rHB29NSsP102A (B), or
rHB2912aaNSs (C) were analyzed at 0 (gray), 8 (red), 14 (blue) and 58 (green) days p.i. Positive ferret serum (black) was added as a control for comparison. Humoral
immune responses were analyzed using a nucleocapsid protein (N)-based ELISA. Optical density (OD) was measured with a spectrometer (iMark Microplate
Reader; Bio-Rad) at 450 nm. The cutoff value was set at an OD value of 0.5 and is indicated as a dashed line in A–C. Serum neutralization assays with rHB29 (D),
CB8/2016 (E), and CB1/2014 (F) virus strains were analyzed by FRNT50 at 0, 8, 14, and 58 d p.i. The asterisks indicate significance compared to the respective serially
diluted day 0 p.i. sample (A–C) or to the rHB29-immunized serum test (D–F), assessed by one-way ANOVAwith Dunnett multiple comparison test. *P < 0.05, **P <
0.01, or *** < 0.0001 (A–C); *P = 0.0165 and **P < 0.0001 (D); *P = 0.0061, **P < 0.0001, (E); and *P = 0.0328, **P < 0.0001, and ***P = 0.0001 (F).
Fig. 5. Survival, relative body weight, temperature change and hematological analysis of immunized ferrets in a lethal challenge model. Six ferrets in each group
were i.m. inoculated with 107.6 TCID50 of CB1/2014. Survival (A) relative body weight (B) and temperature (C) were assessed and are shown as SEM. Data (means ±
SEM) are presented in B and C. Blood from infected ferrets was collected every other day and hematological examination was performed using a Celltac he-
matology analyzer. Platelet counts from ferrets preimmunized with rHB29 (D), rHB29NSsP102A (E), or rHB2912aaNSs (F) and subsequently challenged with CB1/
2014 or animals infected with CB1/2014 only (G) are shown. CB1/2014 infected ferrets were additionally infected for positive control. Normal range of platelet
counts in ferrets are 171.7 to 1,280.6 × 103/μL (46, 58). The dashed lines indicate the normal value range for platelet counts. The asterisks indicate significance
compared to each day p.i. sample. The 2-tailed Mantel–Cox method (A) or the one-way ANOVA with Dunnett multiple comparison test (B–F) was used to assess P
values by the 2-tailed, unpaired t test. *P = 0.0025 (A); *P < 0.02, **P < 0.0001, ***P = 0.0053, ****P = 0.0019, and *****P = 0.0478 (B); *P = 0.0377, **P = 0.0140,
***P < 0.0001, ****P = 0.0025, and *****P = 0.0243 (C); *P = 0.0055 and **P = 0.0124 (E); and *P = 0.0003 and **P = 0.0005 (G).
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At 5 d p.c., 3 animals were killed per group to assess virus
dissemination and tissue tropism in the challenged animals. In
concordance with the initial infection data for CB8/2016 (Fig.
2D), the organ with the highest detectable viral RNA levels
following challenge of the immunized animals was the spleen
(Fig. 6B). Other than the viral RNA detected in the challenge
control group, the greatest amount of viral RNA was detected in
the spleens isolated from the rHB29NSsP102A-immunized and
CB1/2014 challenged group, although this increase was not sta-
tistically significant (mean value of 0.3 log10 viral copies/g).
When the other tissues (e.g., lung, liver, kidney, and intestine)
were examined, no statistically significant increases in viral RNA
levels were detected (Fig. 6B).
Genetic Stability of rHB2912aaNSs. To evaluate the genetic stability
of the NSs-deletant virus (rHB2912aaNSs), we conducted 6 se-
rial passages of rHB2912aaNSs virus through groups of ferrets.
In detail, 2 ferrets were infected with rHB2912aaNSs and the
spleens of the animals were collected at 4 d p.i. for virus isolation
in Vero-E6 cells. Once isolated, the passaged virus was admin-
istered to another pair of animals, until 6 passages had been
recorded. The viral S RNA segment was amplified from each
animals’ splenic tissue by RT-PCR, and the presence of the NSs
truncation was confirmed by sanger sequencing. There were no
nucleotide substitutions detected in the sequence of the S RNA
segment isolated from passaged viruses compared to the original
virus stock. Sequencing results also showed that no revertant
virus was detected after 6 serial passages through sequentially
infected animals.
Discussion
SFTSV is an emerging pathogen of global significance (9, 47).
Since its emergence in China in 2009 (2), the virus has been
isolated in Japan (3), Korea (4), and Vietnam (7). As SFTSV is a
relatively novel disease, therapeutic options are still limited to
the administration of ribavirin, steroids, and/or plasma exchange
in human patients (48). Several companies and laboratories have
been working to develop vaccines against SFTSV (43, 49).
However, there are many hurdles that must be overcome to
successfully produce a useable vaccine, including the establish-
ment of reliable vaccine efficacy testing methods. Firstly, the
creation of proper animal infection models will be necessary to
evaluate vaccine efficacy in vivo. To date, only a few animal
models, such as type I IFN-deficient (35), newborn (37), or
mitomycin-treated mice (38), can recapitulate the fatal illness
seen in human patients following SFTSV infection. However, it
should be noted that type-I IFN-deficient and mitomycin-treated
mouse models are both immunosuppressed systems. This means
they cannot deliver the normal immune response against virus
infection. Hence, a model for SFTSV infection with a normal
immune status is essential to reliably test candidate vaccine ef-
ficacies. Secondly, a standard neutralization testing method will
be needed to evaluate the cross-protective efficacy of novel
vaccines. Recently, serum neutralizing antibody-based testing
methods were reported (50); however, the cross-reactivity of
these antibodies with different SFTSV genotypes still needs to be
evaluated to define a standard strain to be used in vaccine
production.
Here, we describe the evaluation of 2 live-attenuated vaccine
candidates against SFTSV, based on the wild type-derived
rHB29 strain. We demonstrate the immunogenicity of the viruses
following infection and show prior immunization induces pro-
tection against a lethal SFTSV infection in a ferret challenge
model. In our previous study, we demonstrate that the aged
ferret could reproduce SFTS-like pathogenesis following in-
fection and that the resulting disease fully recapitulates the
clinical manifestations of human SFTSV infections. We also
show IFN-mediated antiviral signaling is important for SFTSV
pathogenesis through transcriptomic analysis. These data suggest
that our immune-competent age-dependent ferret model will be
useful for the development of anti-SFTSV therapies and vaccine
development (40). Our results show that both NSs-mutant viru-
ses (rHB29NSsP102A and rHB2912aaNSs) have reduced patho-
genicity in the ferret and infected animals did not display any
SFTS-like clinical disease in comparison to animals infected with
the CB8/2016 strain (genotype D). It is noteworthy that virus
RNA copy number in sera and target organs of rHB2912aaNSs-
infected ferrets were significantly lower than those of the rHB29-
infected ferrets. However, infected ferrets elicited a strong IgG
and a neutralizing antibody response following a single immu-
nization with rHB2912aaNSs. Further, rHB2912aaNSs was only
detected from 4 to 6 d p.i. in the liver and spleens of infected
animals, which are important immune defenses of the body.
Therefore, we hypothesize that the low levels of viral RNA de-
tected in the sera and tissues of rHB2912aaNSs-infected ferrets
result in sufficient antigen presentation in the spleen or liver to
induce a strong, protective, antibody response from a single dose
of virus.
Safety is a major consideration for live-attenuated virus vac-
cines. Concerns regarding a reversion to virulence of the atten-
uated virus by genetic drift are often raised. However, as
rHB2912aaNSs contains a 96% deletion of the NSs ORF rather
than individual residue mutations, there is minimal chance of
virus reversion to wild type through the acquisition of the deleted
gene sequences during passage. When we conducted serial pas-
saging of rHB2912aaNSs virus in vitro and in vivo, no revertant
Fig. 6. Distribution of viral RNA copies in blood and tissues of challenged ferrets. Six ferrets in each group were i.m. inoculated with 107.6 TCID50 of CB1/2014.
At the time points indicated following lethal challenge, serum viral RNA copy numbers were determined by real-time PCR (A). At 5 d p.i., 3 ferrets in each
group were killed, and tissues (lung, liver, kidney, spleen, and intestine) were assessed for viral RNA copy number by real-time PCR (B). The one-way ANOVA
with Dunnett multiple comparison test was used to assess P values compared with each day p.i. of rHB29. *P < 0.0001 and **P = 0.0005 (A); *P = 0.001, **P =
0.0001, and ***P < 0.0001 (B). # No samples were collected as animals had died/been killed.
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virus was detected during multiple sequential passage (up to 6
times in ferrets), demonstrating the genetic stability and safety of
this vaccine candidate. For rHB29NSsP102A, we did not detect a
revertant mutation in cell culture experiments. However, its ge-
netic stability during in vivo passaging remains to be studied.
Genetic segment reassortment of closely related viruses with our
vaccine candidates remains theoretically possible and reassort-
ment is well documented among the Bunyavirales and SFTS
viruses (51). However, any genetic reassortment with
rHB2912aaNSs would result in either an attenuated virus con-
taining the rHB2912aaNSs-derived S RNA segment or the initial
parental viruses.
Recently, genetic and phylogenetic analysis of SFTS viruses
revealed that SFTSV could be grouped into at least 6 different
genotypes referred to as genotypes A to F and that the preva-
lence of SFTSV genotypes are varied dependent on country (52).
Since the recombinant SFTS viruses described herein belonged
to genotype D, the immunized ferrets were subsequently in-
fected with a known lethal dose of a heterologous genotype
B strain (CB1/2014) to evaluate cross-protective efficacy.
These data clearly demonstrate that a single immunization of
rHB29NSsP102A or rHB2912aaNSs is sufficient to confer
heterologous-genotype protection in an aged ferret model when
challenged with a lethal dose of the virulent strain of SFTSV,
CB1/2014. Further, this protective effect was evidenced by a lack
of clinical manifestations, an absence of thrombocytopenia and
reduced virus replication and dissemination to the surrounding
tissues of infected animals.
Further research will need to be undertaken into the devel-
opment of new reverse-genetics systems to fully understand
the differences noted in the in vivo virulence observed between
the Korean-derived isolates (CB1/2014 and CB8/2016) and the
Chinese isolate (HB29) in our ferret model. The sequence of the
recombinant rHB29 virus is based on a strain of SFTSV isolated
from a patient described in Yu et al. (2). As shown in Table 1,
there are several differences between the viral isolates at the
amino acid level in key proteins such as the virulence factor and
innate immune antagonist NSs. The NSs protein of HB29 is only
96.6 and 98.0% similar to the NSs of CB1/2014 or CB8/2016,
respectively. Our own experimental data has demonstrated a
single point mutation (such as P102A) within NSs can dramati-
cally reduce virulence of a virus (31). There is a total of 29 or 50
amino acid substitutions between HB29 and CB8/2016 or CB1/
2014, respectively (SI Appendix, Table S1). Therefore, it is pos-
sible that any of the amino acid changes between the different
isolates could result in the attenuated phenotype observed in
HB29-infected ferrets. Future work should aim to identify and
pinpoint the amino acid changes that increase the pathogenicity
of the Korean isolates.
In conclusion, we evaluated 2 recombinant HB29 derived live-
attenuated SFTSV vaccine candidates and demonstrated their
immunogenicity and protective efficacy using a lethal model for
SFTSV in ferrets. rHB29NSsP102A or rHB2912aaNSs virus in-
fection showed significantly reduced pathogenicity in the aged
ferrets compared with the homologous genotype CB8/2016 strain
(genotype D). Both viruses induced strong IgG and neutralizing
antibody responses against homologous and heterologous
SFTSV strains. In particular, we found that following a single
immunization with rHB29NSsP102A or rHB2912aaNSs ferrets
were completely protected from lethal SFTSV challenge. No
virus RNA was detectable in the serum or organs of preimmu-
nized animals that had been challenged with CB1/2014 (Fig. 6),
demonstrating the induction of sterilizing immunity. This sug-
gests that a live attenuated vaccine platform might represent a
suitable vaccine strategy against SFTSV due to its ability to in-
duce a wider range of immune response types. It was recently
reported that a live attenuated rVSV-based vaccine expressing
the SFTSV Gn/Gc glycoproteins can elicit protection against
SFTSV in immunocompromised IFNAR−/− mice (43); however,
our current study represents a substantial contribution toward
the development of an effective preventive vaccine for SFTS.
Our live attenuated vaccines induced complete protection
against lethal SFTSV challenge in an immunocompetent middle-
sized animal model that exhibits clinical manifestations seen in
SFTS patients (40). Given the genetic diversity of SFTSV in
nature, few prior studies have examined the cross-protective
immunity against heterologous SFTSV genotype infections;
thus, our present study provides valuable insights into the design
of preventive vaccines against SFTSV.
Methods
Cells and Viruses. Vero E6 cell line (commonly used cell line originally obtained
from European Collection of Authenticated Cell Cultures, previously de-
scribed in ref. 53) was grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (FCS). HuH7-Lunet-T7 cells
(54), which stably express T7 RNA polymerase, were obtained from R. Bar-
tenschlager and were grown in DMEM supplemented with 2 mM L-gluta-
mine, nonessential amino acids, and 10% FCS. All cell lines were grown at
37 °C with 5% CO2 unless otherwise stated.
SFTSV strains used in this study were a recombinant derivative of the
Hubei-29 strain generated by reverse genetics (rHB29). This sequence is based
on a plaque-purified stock called Hubei 29pp (HB29pp) provided by Amy
Lambert (CDC Arbovirus Diseases Branch, Division of Vector-Borne Infectious
Diseases, Fort Collins, CO) (55). CB1/2014 and CB8/2016 were isolated from
the sera of SFTSV-infected patients hospitalized with SFTS symptoms at
Chungbuk National University Hospital, South Korea (45). Stock viruses were
generated by propagation of the virus up to a maximum of 5 times from the
original patient sera.
Working stocks of SFTSV were generated in a Vero E6 cell line by infecting
at a low multiplicity of infection and harvesting the cell culture medium 7
d p.i. In vitro experiments with SFTSV conducted in the United Kingdomwere
performed under containment level 3 conditions, approved by the UK Health
and Safety Executive. In Korea, viruses were handled in an enhanced bio-
safety level 3 containment laboratory as approved by the Korean Centres for
Disease Control and Prevention (KCDC-14-3-07).
Plasmids. Plasmids for the recovery of SFTSV have been described previously
(55). pTM1-HB29ppL and pTM1-HB29N contain the SFTSV HB29 L and N ORFs
under the control of T7 promoter and encephalomyocarditis virus internal
ribosome entry site sequence; pTVT7-HB29S, pTVT7- HB29M, and pTVT7-
HB29ppL contain full-length complementary DNAs to the SFTSV strain
HB29 antigenome segments flanked by T7 promoter and hepatitis delta
ribozyme sequences. Plasmid pTVT7-HB29S12aaNSs, which was previously
described (33), contains an internal deletion in the coding region of NSs (Δ2-
282), leaving the methionine and last 11 amino acids of the NSs ORF intact.
The plasmid was used in the recovery of rHB2912aaNSs. Plasmids used to
generate rHB29NSsP102A were described in previous work (31). All cDNA
constructs were confirmed by Sanger sequencing. Recombinant viruses were
recovered from cDNA plasmid transfection as previously described (33, 55).
Virus Titration by Plaque- or Focus- Forming Assays. Virus titres were de-
termined by focus-forming assays or by plaque assay in Vero E6 cells. Briefly,
confluent monolayers of Vero E6 cells were infected with serial dilutions of
virus made in phosphate-buffered saline (PBS) containing 2% FCS and in-
cubated for 1 h at 37 °C, followed by the addition of a Glasgow’s Minimum
Essential Medium overlay supplemented with 2% FCS and 0.6% Avicel (FMC
Biopolymer). The cells were incubated for 6 d before fixation and staining
Table 1. Comparison of percentage amino acid sequence
identities of strains used in this study to the published sequence
of HB29 (AJD86038 [L], AJD86039 [M], AJD86041 [NSs],
AJD86040 [N])
Genotype Strain
Amino acid sequence identity, %
L (RdRp) M (Gn/Gc) S (N) S (NSs)
Genotype B CB1/2014 99.1 97.7 98.8 96.6
Genotype D CB8/2016 99.4 98.5 99.6 98.0
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with crystal violet to visualize SFTSV plaques, or using focus-forming assays
for recombinant viruses as described previously (33, 55).
Infection of Ferrets with Recombinant Viruses. Groups of aged ferrets (>4 y
old; n = 12) were infected via the i.m. route with rHB29 (4 × 106 PFUs),
rHB29NSsP102A (4 × 106 PFUs), rHB2912aaNSs (5 × 105 PFUs), and CB8/2016
(5 × 105 PFUs). Blood was collected from anesthetized ferrets at intervals of 2
d until 12 d p.i. for virus titrations. In addition, 500-μL blood samples were
immediately stored in ethylenediaminetetraacetic acid (EDTA) tubes (MED-
ISTAR, Seoul, Korea) and analyzed for hematological parameters using a
Celltac hematology analyzer (MEK-6550J/K; Nihon Kohden). To assess virus
replication in SFTSV-infected ferrets, 3 ferrets from each group were scari-
fied at 4 and 6 d p.i., and tissues (lung, liver, spleen, kidney, and intestine)
were collected to assess viral RNA loads.
Quantification of Viral Copy Numbers by qRT-PCR. Total RNA from infected
ferret sera and organ tissues was extracted using TRIzol LS Reagent (Thermo
Fisher Scientific), and cDNA was generated by reverse transcription with
specific (SFTSV-S) and random (Takara) primers using the M-MLV Reverse
Transcriptase (Enzynomics). Viral copy numbers were determined by quan-
titative real-time RT-PCR using an S segment-based SFTSV-specific primer set:
forward primer (SFTSV-S-F), gcagttggaatcaggga; and reverse primer (SFTSV-S-
R), cccacttggacatgtgct. Copy numbers were calculated as a ratio with respect
to the standard control as previously described (36), and real-time PCR re-
actions were performed using a SYBR Green Supermix (Bio-Rad) and a CFX96
Touch Real-Time PCR Detection System (Bio-Rad). The limit of detection of
qRT-PCR was 2 RNA genome copies per reaction.
SFTSV Antibodies Detected by ELISA and Virus Neutralization Assay. For the
SFTSV ELISA, plates were coated overnight at 4 °C with purified nucleocapsid
protein (0.2 μg/well) of CB1/2014 strain as previously described (56). Ferret
sera was heat inactivated and treated with kaolin to reduce nonspecific
binding. For the ELISA experiment, serum was collected from CB1/2014 in-
fected ferrets and was used as a positive control in the data presented.
Briefly, serum samples were diluted 1:10, followed by 2-fold dilution series in
PBS from 1:10 to 1:2,560. After washing, the plates were incubated with
100 μL of diluted ferret serum with 2% skim milk in 0.05% PBS-Tween 20 for
2 h at room temperature. Plates were then incubated with horse radish
peroxidase (HRP)–anti-ferret IgG (KPL). For detection of antibodies, the
plates were overlaid with O-phenylenediamine dihydrochloride (Sigma)
substrate and 1 M sulfuric acid was added. OD was measured with a spec-
trometer (iMark Microplate Reader; Bio-Rad) at 450 nm.
Ferret sera were collected at 0, 8, 14, and 58 d after the last inoculation and
neutralizing antibody was measured by FRNT50 as previously described (57).
Briefly, heat-inactivated, 1:10-diluted sera were used to neutralize virus.
Twenty-five microliters of serially diluted serum were mixed with an equal
volume of 200 focus-forming units of each SFTSV strain (rHB29, CB8/2016,
and CB1/2014) for 1 h 37 °C. The mixture was adsorbed on to Vero E6 cells in
96-well plate at 37 °C for 1 h. Cells were overlaid with maintenance medium,
and the plates were incubated 37 °C in 5% CO2 for 5 d. The infected cells
then were fixed with 10% formalin, and the foci formation was visualized
with an in house-generated mouse anti-N antibody, followed by a HRP-
conjugated anti-mouse IgG secondary antibody (The Jackson Laboratory).
The antibody titers were expressed as reciprocals of the highest serum di-
lution showing a 50% plaque reduction or greater compared with
control values.
Lethal Challenge of SFTSV in Ferrets. Ferrets immunized with recombinant
viruses or PBS-preimmunized control animals were challenged i.m. with
107.6 TCID50 of CB1/2014 strain (0.5 mL in the outside of each thigh of both
legs). Throughout the ferret challenge studies, we used a TCID50 dose
(∼107.6) of SFTSV. This dose is known to cause 100% fatality rate in infected
ferrets, as seen in our recent study (40). Survival was monitored for 14 d after
lethal SFTSV challenge with CB1/2014. Sera were collected from each ferret
at 2-d intervals after infection and peripheral virus RNA copy numbers were
determined. Hematological parameters were analyzed using EDTA-treated
whole-blood samples from infected animals using the Celltac hematology
analyzer (MEK-6550J/K; Nihon Kohden). Biochemical parameters of serum
from infected animals were determined using Celltac α (MEK-6550;
Nihon Kohden).
Ethics Statement. All animal experiments were approved by the Medical
Research Institute, a member of Laboratory Animal Research Centre of
Chungbuk National University (approval no. CBNUA-1234-18-01) and were
conducted in strict accordance and adherence to relevant policies regarding
animal handling as mandated under the Guidelines for Animal Use and Care
of the Korea Centre for Disease Control.
Data Availability. The raw data that underpin the findings of this study are
openly available from Enlighten Research Data at https://dx.doi.org/10.5525/
gla.researchdata.897. Authors will make reagents described in this study
available on request (by qualified researchers for their own use). Requests
should be directed to the corresponding authors Y.K.C. or B.B.
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